Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment.
anti-obesity agents
glucagon-like peptide 1
liraglutide
neoplasms
obesity
weight loss
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
25 Aug 2023
25 Aug 2023
Historique:
received:
08
08
2023
revised:
23
08
2023
accepted:
24
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
It is now established that obesity is related to a higher incidence of cancer during a lifespan. The effective treatment of obesity opens up new perspectives in the treatment of a relevant modifiable cancer risk factor. The present narrative review summarizes the correlations between weight loss in obesity and cancer. The current knowledge between obesity treatment and cancer was explored, highlighting the greatest potential for its use in the treatment of cancer in the clinical setting. Evidence for the effects of obesity therapy on proliferation, apoptosis, and response to chemotherapy is summarized. While more studies, including large, long-term clinical trials, are needed to adequately evaluate the relationship and durability between anti-obesity treatment and cancer, collaboration between oncologists and obesity treatment experts is increasingly important.
Identifiants
pubmed: 37686769
pii: nu15173737
doi: 10.3390/nu15173737
pmc: PMC10490004
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Cell Endocrinol. 2016 Nov 15;436:240-9
pubmed: 27496641
J Exp Clin Cancer Res. 2018 Dec 19;37(1):319
pubmed: 30567565
Lancet Diabetes Endocrinol. 2020 Mar;8(3):216-225
pubmed: 32027851
BMC Cancer. 2018 Jun 15;18(1):657
pubmed: 29907137
Prostate. 2020 Apr;80(5):367-375
pubmed: 31967357
Life Sci. 2022 Apr 1;294:120370
pubmed: 35124000
Front Endocrinol (Lausanne). 2022 Jul 11;13:927859
pubmed: 35898463
J Diabetes Investig. 2020 Sep;11(5):1137-1149
pubmed: 32146725
Diabetes. 2014 Nov;63(11):3891-905
pubmed: 24879833
Horm Metab Res. 2022 Jul;54(7):458-471
pubmed: 35512849
Anticancer Res. 2019 Jul;39(7):3815-3822
pubmed: 31262909
Ann Oncol. 2005 Aug;16(8):1253-67
pubmed: 15870086
JNCI Cancer Spectr. 2019 Aug 09;3(4):pkz054
pubmed: 31737862
Diabetes Obes Metab. 2014 Sep;16(9):850-60
pubmed: 24641303
Front Pharmacol. 2022 Oct 25;13:925377
pubmed: 36386208
Diabetes Care. 2012 Apr;35(4):731-7
pubmed: 22442396
Endocr Rev. 2021 Mar 15;42(2):101-132
pubmed: 33320179
Cancers (Basel). 2021 Aug 19;13(16):
pubmed: 34439328
J Endocrinol Invest. 2013 Feb;36(2):140-5
pubmed: 23481614
World J Gastroenterol. 2022 Jul 7;28(25):2881-2889
pubmed: 35978867
Lancet Diabetes Endocrinol. 2021 Sep;9(9):595-605
pubmed: 34358471
Nutrients. 2022 Jan 21;14(3):
pubmed: 35276833
J Clin Invest. 2001 Oct;108(8):1167-74
pubmed: 11602624
Diabetes Metab Syndr Obes. 2021 Jun 10;14:2619-2629
pubmed: 34140791
J Clin Endocrinol Metab. 2021 Mar 8;106(3):912-921
pubmed: 33248445
BMJ Open. 2022 Oct 7;12(10):e062288
pubmed: 36207046
Cancer Metastasis Rev. 2022 Sep;41(3):491-515
pubmed: 36038791
Curr Obes Rep. 2021 Mar;10(1):14-30
pubmed: 33410104
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
J Clin Oncol. 2012 Jul 20;30(21):2593-600
pubmed: 22564993
J Natl Cancer Inst. 2021 Nov 2;113(11):1465-1475
pubmed: 33620467
Front Endocrinol (Lausanne). 2019 Apr 12;10:155
pubmed: 31031702
Endocrinology. 2011 Sep;152(9):3362-72
pubmed: 21771884
Endocr Res. 2022 Feb;47(1):18-25
pubmed: 34459679
Eur J Pharmacol. 2020 Jul 5;878:173102
pubmed: 32283060
Mol Oncol. 2021 Mar;15(3):790-800
pubmed: 32741068
Diabetes Care. 2016 Feb;39(2):198-205
pubmed: 26285584
Br J Cancer. 2021 Mar;124(6):1057-1065
pubmed: 33235316
Endocrine. 2019 Nov;66(2):157-165
pubmed: 31420784
J Mol Endocrinol. 2020 Feb;64(2):103-113
pubmed: 31855560
EBioMedicine. 2021 Mar;65:103242
pubmed: 33684886
Curr Obes Rep. 2019 Jun;8(2):156-164
pubmed: 30874963
BMJ. 2016 Oct 20;355:i5340
pubmed: 27797785
J Clin Oncol. 2016 Dec 10;34(35):4203-4216
pubmed: 27903149
JAMA Oncol. 2019 Feb 1;5(2):155-163
pubmed: 30520976
Am J Pathol. 2010 Jan;176(1):496-503
pubmed: 19948826
Front Endocrinol (Lausanne). 2020 Oct 06;11:563816
pubmed: 33123088
Biomed Pharmacother. 2018 Oct;106:1364-1369
pubmed: 30119208
Cell Metab. 2018 Apr 3;27(4):740-756
pubmed: 29617641
Endocr Pract. 2016 Jul;22 Suppl 3:1-203
pubmed: 27219496
Am J Physiol Endocrinol Metab. 2014 Jun 15;306(12):E1431-41
pubmed: 24801389
Epidemiology. 2022 Jul 1;33(4):563-571
pubmed: 35394977
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Int J Mol Sci. 2022 Jun 10;23(12):
pubmed: 35742944
Anticancer Res. 2017 Nov;37(11):6321-6327
pubmed: 29061815
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
BMC Cancer. 2022 May 14;22(1):546
pubmed: 35568802
Prostate. 2018 Nov;78(15):1125-1133
pubmed: 30009503
JAMA. 2022 May 24;327(20):1963-1973
pubmed: 35608580
NPJ Breast Cancer. 2020 Feb 21;6:6
pubmed: 32133391
J Clin Invest. 2014 Oct;124(10):4473-88
pubmed: 25202980
Cancer Cell Int. 2021 Sep 10;21(1):481
pubmed: 34507580
Diabetes Metab Syndr Obes. 2020 Sep 29;13:3325-3335
pubmed: 33061494
Dose Response. 2021 Feb 22;19(1):1559325821995651
pubmed: 33746653
Mol Med Rep. 2018 Apr;17(4):5202-5212
pubmed: 29393459
Diabetes Care. 2018 Aug;41(8):1663-1671
pubmed: 29898902
ScientificWorldJournal. 2014 Mar 24;2014:694326
pubmed: 24782665
Endocrine. 2020 Jun;68(3):518-525
pubmed: 32103407
JAMA. 2021 Apr 13;325(14):1414-1425
pubmed: 33755728
Transl Oncol. 2020 Apr;13(4):100760
pubmed: 32247264
BMC Med. 2022 Oct 24;20(1):402
pubmed: 36280839
J Clin Lab Anal. 2022 Oct;36(10):e24604
pubmed: 35989517
Cancer Prev Res (Phila). 2014 Sep;7(9):867-85
pubmed: 24985407
Int J Obes (Lond). 2021 Sep;45(9):1886-1898
pubmed: 34088971
Cancer Prev Res (Phila). 2015 Oct;8(10):888-94
pubmed: 26276754
Diabet Med. 2005 May;22(5):654-7
pubmed: 15842525
Int J Environ Res Public Health. 2022 Jan 27;19(3):
pubmed: 35162468
Obes Rev. 2017 Jul;18(7):715-723
pubmed: 28489290
Drug Des Devel Ther. 2022 Oct 25;16:3723-3735
pubmed: 36304787
N Engl J Med. 2021 Mar 18;384(11):989-1002
pubmed: 33567185
Nature. 2022 Aug;608(7922):421-428
pubmed: 35922508
Diabetes Care. 2018 Mar;41(3):620-622
pubmed: 29279300
Exp Clin Endocrinol Diabetes. 2017 Feb;125(2):91-97
pubmed: 28008585
JAMA. 2022 Jan 11;327(2):138-150
pubmed: 35015037
Cochrane Database Syst Rev. 2018 Feb 01;2:CD012513
pubmed: 29388687
Front Endocrinol (Lausanne). 2021 Jul 07;12:645563
pubmed: 34305810
Diabetes Obes Metab. 2017 Sep;19(9):1242-1251
pubmed: 28266779
Front Pharmacol. 2022 Aug 10;13:901559
pubmed: 36034798
Int J Mol Sci. 2020 Nov 12;21(22):
pubmed: 33198356
Endocr Connect. 2017 Nov;6(8):856-865
pubmed: 29042458
JAMA. 2022 Jun 28;327(24):2423-2433
pubmed: 35657620
JAMA. 2021 Apr 13;325(14):1403-1413
pubmed: 33625476
Prostate Cancer Prostatic Dis. 2022 Sep;25(3):411-421
pubmed: 34987170
Diabetologia. 2017 Sep;60(9):1639-1647
pubmed: 28776080
Lancet. 2022 Jan 15;399(10321):259-269
pubmed: 34895470
Endocr Pract. 2017 Mar;23(3):372-378
pubmed: 27967229
Lancet Diabetes Endocrinol. 2015 Nov;3(11):866-75
pubmed: 26377054
Endocr Rev. 2022 May 12;43(3):507-557
pubmed: 35552683
Circ Res. 2016 Aug 19;119(5):652-65
pubmed: 27418629
Endocrinology. 2017 Dec 1;158(12):4218-4232
pubmed: 29045658
Chem Biol Interact. 2021 Nov 1;349:109641
pubmed: 34534549